Portola Pharmaceuticals Competitors and Similar CompaniesClear all

Portola Pharmaceuticals's competitors and similar companies include Acceleron Pharma, Genentech and Cipla.

	Portola Pharmaceuticals Portola Pharmaceuticals is a biopharmaceutical company.	Acceleron Pharma Acceleron Pharma is a clinical-stage biopharmaceutical company.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
Founding Date	Founding Date 2003	Founding Date 2003	Founding Date 1976	Founding Date 1935
Type	Type Subsidiary	Type Subsidiary	Type Subsidiary	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma
Locations	Locations South San Francisco, US HQ Planegg, DE Amsterdam, NL	Locations Cambridge, US HQ Zug, CH	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more
Employees	Employees 55	Employees 636% decrease	Employees 18,077	Employees 27,764
Financial
Revenue (est.)	Revenue (est.) $116.6m (FY, 2019)	Revenue (est.) $92.5m (FY, 2020)	Revenue (est.) N/A	Revenue (est.) ₹277.1b (FY, 2026)
Cost of goods	Cost of goods $44.4m (FY, 2019)	Cost of goods N/A	Cost of goods N/A	Cost of goods ₹97.2b (FY, 2026)
Gross profit	Gross profit $72.3m (FY, 2019)	Gross profit N/A	Gross profit N/A	Gross profit ₹184.4b (FY, 2026)
Net income	Net income ($290.7m) (FY, 2019)	Net income ($166m) (FY, 2020)	Net income N/A	Net income ₹38.7b (FY, 2026)
Funding
Total funding raised	Total funding raised $ 295.1m	Total funding raised $ 141.8m	Total funding raised N/A	Total funding raised N/A